Relay Therapeutics Reports Early Success For Investigational Drug In Rare Vascular Disorders

All NewsMay 19, 2026

Relay Therapeutics reported early Phase 2 data showing lesion reduction and symptom improvement with zovegalisib.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT